These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425 [TBL] [Abstract][Full Text] [Related]
6. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Geisbert TW; Lee AC; Robbins M; Geisbert JB; Honko AN; Sood V; Johnson JC; de Jong S; Tavakoli I; Judge A; Hensley LE; Maclachlan I Lancet; 2010 May; 375(9729):1896-905. PubMed ID: 20511019 [TBL] [Abstract][Full Text] [Related]
7. Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants. Versteeg K; Menicucci AR; Woolsey C; Mire CE; Geisbert JB; Cross RW; Agans KN; Jeske D; Messaoudi I; Geisbert TW Sci Rep; 2017 Aug; 7(1):9730. PubMed ID: 28852031 [TBL] [Abstract][Full Text] [Related]
8. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Pratt WD; Wang D; Nichols DK; Luo M; Woraratanadharm J; Dye JM; Holman DH; Dong JY Clin Vaccine Immunol; 2010 Apr; 17(4):572-81. PubMed ID: 20181765 [TBL] [Abstract][Full Text] [Related]
9. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. Geisbert TW; Daddario-DiCaprio KM; Williams KJ; Geisbert JB; Leung A; Feldmann F; Hensley LE; Feldmann H; Jones SM J Virol; 2008 Jun; 82(11):5664-8. PubMed ID: 18385248 [TBL] [Abstract][Full Text] [Related]
11. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. Marzi A; Yoshida R; Miyamoto H; Ishijima M; Suzuki Y; Higuchi M; Matsuyama Y; Igarashi M; Nakayama E; Kuroda M; Saijo M; Feldmann F; Brining D; Feldmann H; Takada A PLoS One; 2012; 7(4):e36192. PubMed ID: 22558378 [TBL] [Abstract][Full Text] [Related]
12. Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. Wong G; Qiu X; de La Vega MA; Fernando L; Wei H; Bello A; Fausther-Bovendo H; Audet J; Kroeker A; Kozak R; Tran K; He S; Tierney K; Soule G; Moffat E; Günther S; Gao GF; Strong J; Embury-Hyatt C; Kobinger G J Infect Dis; 2016 Oct; 214(suppl 3):S281-S289. PubMed ID: 27651412 [TBL] [Abstract][Full Text] [Related]
13. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083 [TBL] [Abstract][Full Text] [Related]
14. Human Polyclonal Antibodies Produced by Transchromosomal Cattle Provide Partial Protection Against Lethal Zaire Ebolavirus Challenge in Rhesus Macaques. Rosenke K; Bounds CE; Hanley PW; Saturday G; Sullivan E; Wu H; Jiao JA; Feldmann H; Schmaljohn C; Safronetz D J Infect Dis; 2018 Nov; 218(suppl_5):S658-S661. PubMed ID: 30053153 [TBL] [Abstract][Full Text] [Related]
15. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Jahrling PB; Geisbert J; Swearengen JR; Jaax GP; Lewis T; Huggins JW; Schmidt JJ; LeDuc JW; Peters CJ Arch Virol Suppl; 1996; 11():135-40. PubMed ID: 8800795 [TBL] [Abstract][Full Text] [Related]